US EditionPublished • loading... • Updated
Harbour Makes $90M Upfront Deal with Bristol Myers for New Antibodies
The collaboration combines proprietary antibody platforms to accelerate multi-specific antibody programs with potential payments exceeding $1 billion, aiming for transformative immunology and oncology therapies.
- Dec. 16, 2025, Harbour BioMed announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.
- By combining Harbour Mice platform, HBICE and single B cell cloning platform, Harbour BioMed aims to unite its strengths with Bristol Myers Squibb's expertise to accelerate antibody discovery and development.
- Harbour Mice produces fully human monoclonal antibodies in H2L2 and HCAb formats, and HBICE leverages HCAb to create bispecific immune cell engagers that the company says enhance tumor-killing effects.
- Under the agreement, Harbour BioMed could receive $90 million plus up to $1.035 billion in milestones and tiered royalties, with potential early clinical trials in China.
- The collaboration positions Harbour BioMed to progress programs and deliver transformative antibody therapies to patients worldwide, aligning with its strategy to build a differentiated pipeline and portfolio.
Insights by Ground AI
18 Articles
18 Articles
LoudounTimes.com+16 Reposted by 16 other sources
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration…
Coverage Details
Total News Sources18
Leaning Left3Leaning Right1Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 33%
C 56%
11%
Factuality
To view factuality data please Upgrade to Premium
